Midkine as a potential diagnostic marker in epithelial ovarian cancer for cisplatin/paclitaxel combination clinical therapy.

Wu, Xiaoqing; Zhi, Xiaogai; Ji, Minghua; Wang, Qingling; Li, Yujuan; Xie, Jingyan; Zhao, Shuli

Wu, Xiaoqing; Zhi, Xiaogai; Ji, Minghua; Wang, Qingling; Li, Yujuan; Xie, Jingyan; Zhao, Shuli.

Afiliação

Wu X; Nanjing First Hospital, Nanjing Medical University Nanjing, China.
Zhi X; Nanjing First Hospital, Nanjing Medical University Nanjing, China.
Ji M; Jiangsu Cancer Hospital Nanjing, China.
Wang Q; Department of Pathology, Xuzhou Medical College Xuzhou, China.
Li Y; Nanjing First Hospital, Nanjing Medical University Nanjing, China.
Xie J; Nanjing First Hospital, Nanjing Medical University Nanjing, China.
Zhao S; Nanjing First Hospital, Nanjing Medical University Nanjing, China ; State Key Laboratory of Reproductive Medicine, Nanjing Medical University Nanjing, China.

Am J Cancer Res ; 5(2): 629-38, 2015.

Article em En | MEDLINE | ID: mdl-25973302

Palavras-chave

Epithelial ovarian cancer (EOC); cisplatin/paclitaxel combination therapy; drug sensitivity; immunostaining; midkine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Am J Cancer Res Ano de publicação: 2015 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google